Jupiter Neurosciences Income from Continuous Operations 2023-2025 | JUNS

Jupiter Neurosciences income from continuous operations from 2023 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change

Jupiter Neurosciences Income from Continuous Operations 2023-2025 | JUNS

Jupiter Neurosciences income from continuous operations from 2023 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$70.5B
Zoetis (ZTS)$69.4B
Takeda Pharmaceutical (TAK)$49.4B
Daiichi Sankyo, - (DSNKY)$48.3B
BeOne Medicines - (ONC)$34.4B
Sandoz Group AG (SDZNY)$27.6B
Summit Therapeutics (SMMT)$19.5B
Merck (MKKGY)$17B
Shionogi (SGIOY)$14.9B
United Therapeutics (UTHR)$14.1B
Neurocrine Biosciences (NBIX)$13.4B
IPSEN (IPSEY)$11.4B
Orion OYJ (ORINY)$11.3B
Eisai (ESAIY)$9.3B
Madrigal Pharmaceuticals (MDGL)$9.2B
Corcept Therapeutics (CORT)$7.4B
Grifols, S.A (GRFS)$7B
Stevanato Group S.p.A (STVN)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
Procaps Group, S.A (PROCF)$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.6B
Hypermarcas (HYPMY)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B